SI1648507T1 - Metode in sestavki za povečanje učinkovitosti terapevtskih protiteles z uporabo potenciranja spojin nk celice - Google Patents

Metode in sestavki za povečanje učinkovitosti terapevtskih protiteles z uporabo potenciranja spojin nk celice

Info

Publication number
SI1648507T1
SI1648507T1 SI200432379A SI200432379A SI1648507T1 SI 1648507 T1 SI1648507 T1 SI 1648507T1 SI 200432379 A SI200432379 A SI 200432379A SI 200432379 A SI200432379 A SI 200432379A SI 1648507 T1 SI1648507 T1 SI 1648507T1
Authority
SI
Slovenia
Prior art keywords
compositions
increasing
efficiency
methods
therapeutic antibodies
Prior art date
Application number
SI200432379A
Other languages
English (en)
Inventor
Andrea Velardi
Francois Romagne
Original Assignee
Innate Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma S.A. filed Critical Innate Pharma S.A.
Publication of SI1648507T1 publication Critical patent/SI1648507T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
SI200432379A 2003-07-24 2004-07-23 Metode in sestavki za povečanje učinkovitosti terapevtskih protiteles z uporabo potenciranja spojin nk celice SI1648507T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48948903P 2003-07-24 2003-07-24
PCT/IB2004/002636 WO2005009465A1 (en) 2003-07-24 2004-07-23 Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
EP04744267.8A EP1648507B1 (en) 2003-07-24 2004-07-23 Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds

Publications (1)

Publication Number Publication Date
SI1648507T1 true SI1648507T1 (sl) 2017-07-31

Family

ID=34102889

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200432379A SI1648507T1 (sl) 2003-07-24 2004-07-23 Metode in sestavki za povečanje učinkovitosti terapevtskih protiteles z uporabo potenciranja spojin nk celice

Country Status (22)

Country Link
US (3) US7803376B2 (sl)
EP (2) EP1648507B1 (sl)
JP (3) JP5642328B2 (sl)
KR (2) KR101299599B1 (sl)
CN (3) CN104645327A (sl)
AU (1) AU2004258747B2 (sl)
BR (1) BRPI0412890B8 (sl)
CA (1) CA2532547C (sl)
CY (1) CY1118978T1 (sl)
DK (1) DK1648507T3 (sl)
ES (1) ES2619171T3 (sl)
HR (1) HRP20170342T1 (sl)
HU (1) HUE033129T2 (sl)
IL (1) IL172679A (sl)
LT (1) LT1648507T (sl)
NO (2) NO337619B1 (sl)
PL (1) PL1648507T3 (sl)
PT (1) PT1648507T (sl)
RU (1) RU2396981C2 (sl)
SI (1) SI1648507T1 (sl)
WO (1) WO2005009465A1 (sl)
ZA (1) ZA200601584B (sl)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20070148171A1 (en) * 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060235208A1 (en) * 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20070275460A1 (en) * 2003-03-03 2007-11-29 Xencor.Inc. Fc Variants With Optimized Fc Receptor Binding Properties
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
US20090191213A9 (en) * 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
PL1639013T3 (pl) * 2003-07-02 2013-02-28 Innate Pharma Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu
EP1648507B1 (en) 2003-07-24 2017-01-25 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
EP1648508A1 (en) * 2003-07-24 2006-04-26 Universita Degli Studi Di Perugia Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
US7276585B2 (en) * 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
EP1791868B1 (en) * 2004-07-01 2011-02-23 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
EP2412728B1 (en) 2004-08-03 2015-01-07 Innate Pharma Therapeutic compositions against cancer targeting 4IG-B7-H3
US20060074225A1 (en) * 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) * 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8993319B2 (en) 2004-12-28 2015-03-31 Innate Pharma S.A. Monoclonal antibodies against NKG2A
DK1835937T3 (da) 2005-01-06 2012-07-23 Novo Nordisk As Sammensætninger og fremgangsmåder til behandling af virusinfektion
WO2006072626A1 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Kir-binding agents and methods of use thereof
ES2732623T3 (es) 2005-01-06 2019-11-25 Innate Pharma Sa Tratamientos y métodos de combinación anti-KIR
CA2595169A1 (en) * 2005-01-12 2006-07-20 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
JP2008540569A (ja) * 2005-05-12 2008-11-20 ザイモジェネティクス， インコーポレイテッド 免疫系を調整するためにＢ７ファミリーメンバーであるｐＮＫｐ３０を使用する方法
DK1931709T3 (en) * 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
EP1951757B1 (en) 2005-10-06 2014-05-14 Xencor, Inc. Optimized anti-cd30 antibodies
US9447185B2 (en) 2005-10-14 2016-09-20 Innate Pharma, S.A. Compositions and methods for treating proliferative disorders
BRPI0712953B8 (pt) * 2006-06-30 2021-05-25 Novo Nordisk As anticorpos anti-nkg2a, seu uso, e composição farmacêutica
PL2059536T3 (pl) 2006-08-14 2014-07-31 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
CA2660795C (en) * 2006-09-18 2014-11-18 Xencor, Inc. Optimized antibodies that target hm1.24
US7580304B2 (en) * 2007-06-15 2009-08-25 United Memories, Inc. Multiple bus charge sharing
JP5490714B2 (ja) * 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
CA3102704A1 (en) 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
EP4269443A3 (en) 2007-12-26 2023-12-27 Xencor, Inc. Fc variants with altered binding to fcrn
CN101952317B (zh) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 人化抗-人nkg2a单克隆抗体
EP2367553B1 (en) 2008-12-05 2017-05-03 Novo Nordisk A/S Combination therapy to enhance nk cell mediated cytotoxicity
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CA2787157A1 (en) * 2010-02-11 2011-08-18 F. Hoffmann-La Roche Ag 3d adcc nk facs assay
CN105640964A (zh) * 2010-04-21 2016-06-08 文蒂雷克斯药品公司 增强抗体依赖性细胞的细胞毒性的方法
CN103298831A (zh) * 2010-11-22 2013-09-11 伊纳特医药股份有限公司 Nk细胞调节治疗和用于治疗血液恶性疾病的方法
KR102046666B1 (ko) 2011-05-25 2019-11-19 이나뜨 파르마 염증성 장애의 치료를 위한 항-kir 항체
AU2012268939B2 (en) 2011-06-17 2017-05-04 Novo Nordisk A/S Selective elimination of erosive cells
EP2723362A1 (en) 2011-06-21 2014-04-30 Innate Pharma NKp46-MEDIATED NK CELL TUNING
SG11201502496WA (en) 2012-10-02 2015-04-29 Bristol Myers Squibb Co Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
JP6553515B2 (ja) * 2012-12-20 2019-07-31 メディミューン，エルエルシー 免疫複合体の製造方法
ES2878749T3 (es) * 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
ES2707057T3 (es) 2013-11-06 2019-04-02 Bristol Myers Squibb Co Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
CN106132989B (zh) * 2014-03-14 2020-06-19 先天制药公司 具有增加的稳定性的人源化抗体
EP3149045B1 (en) * 2014-05-27 2023-01-18 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10519234B2 (en) * 2014-06-27 2019-12-31 Innate Pharma NKp46 binding proteins
HUE051193T2 (hu) * 2014-09-16 2021-03-01 Innate Pharma Gátlási reakcióút semlegesítése limfocitákban
US10316094B2 (en) 2014-10-24 2019-06-11 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
US10550187B2 (en) 2014-10-24 2020-02-04 Incept, Llc Extra luminal scaffold
SG11201708223QA (en) 2015-04-17 2017-11-29 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EP3907285A1 (en) 2015-05-06 2021-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CA2991469A1 (en) * 2015-07-07 2017-01-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for enhancing nk cell killing activities
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
JP6944925B2 (ja) * 2015-07-24 2021-10-06 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 組織浸潤ｎｋ細胞を検出する方法
KR102713140B1 (ko) * 2015-08-11 2024-10-07 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 항체
RU2770001C2 (ru) 2015-10-06 2022-04-14 Риджентс Оф Дзе Юниверсити Оф Миннесота Терапевтические соединения и способы
KR20180104597A (ko) 2015-11-07 2018-09-21 멀티비르 인코포레이티드 암 치료를 위한 종양 억제 유전자 요법 및 면역관문 봉쇄를 포함하는 조성물
ES2905823T3 (es) 2016-05-20 2022-04-12 Biohaven Therapeutics Ltd Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US10858431B2 (en) * 2016-06-30 2020-12-08 Trellis Bioscience, Llc Monoclonal antibodies targeting killer immunoglobulin-like receptor (KIR) family signaling
US20190300606A1 (en) * 2016-07-01 2019-10-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory Immune Receptor Inhibition Methods and Compositions
CN106635998B (zh) * 2016-09-14 2018-01-09 深圳市默赛尔生物医学科技发展有限公司 抗体调控的双抗原特异性t细胞及其制备方法和应用
EP3518946A4 (en) 2016-09-27 2020-09-09 Board of Regents, The University of Texas System METHODS TO IMPROVE IMMUNE CHECKPOINT BLOCKING TREATMENT BY MODULATING THE MICROBIOME
KR102661905B1 (ko) 2016-10-12 2024-04-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Tusc2 면역요법을 위한 방법 및 조성물
JP2020510624A (ja) 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
CA3235295A1 (en) 2017-02-20 2018-08-23 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
JP7458188B2 (ja) 2017-03-31 2024-03-29 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍を処置する方法
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
JP6647240B2 (ja) 2017-05-12 2020-02-14 米満　吉和 高活性ｎｋ細胞、およびその利用
EP3444276A1 (en) 2017-08-17 2019-02-20 Onkocellular Limited Improved cancer treatment using nk cells
AU2018346955B2 (en) 2017-10-13 2024-08-29 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
CN111247169A (zh) 2017-10-15 2020-06-05 百时美施贵宝公司 治疗肿瘤的方法
US11884733B2 (en) 2018-02-08 2024-01-30 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the NKG2D receptor
CA3094329A1 (en) 2018-03-19 2020-02-20 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer
US11242393B2 (en) 2018-03-23 2022-02-08 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019246043B2 (en) 2018-03-25 2024-07-04 Snipr Biome Aps. Treating and preventing microbial infections
EP3774911A1 (en) 2018-03-30 2021-02-17 Bristol-Myers Squibb Company Methods of treating tumor
EA202091888A1 (ru) * 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
SG11202104969RA (en) 2018-11-16 2021-06-29 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
MX2021007271A (es) 2018-12-21 2021-07-15 Onxeo Nuevas moleculas de acido nucleico conjugado y sus usos.
EP3976831A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
CN115803037A (zh) * 2020-06-30 2023-03-14 盖亚生物制药有限公司 稳定nk细胞与抗体的结合的方法及其应用
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
IL300588A (en) 2020-08-12 2023-04-01 Biond Biologics Ltd Antibodies against ILT-2 and their use
IL300916A (en) 2020-08-31 2023-04-01 Bristol Myers Squibb Co Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
IL303648A (en) 2020-12-28 2023-08-01 Bristol Myers Squibb Co Antibody preparations and methods of using them
CA3196999A1 (en) 2020-12-28 2022-07-07 Masano HUANG Methods of treating tumors
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2023081813A1 (en) 2021-11-05 2023-05-11 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
CN118660964A (zh) 2021-12-16 2024-09-17 瓦莱里奥治疗公司 新型缀合核酸分子及其用途
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240182A1 (en) 2022-06-08 2023-12-14 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR401702A (fr) 1908-08-04 1909-09-13 Charles Marenghi Et Cie Soc Dispositif permettant d'imiter mécaniquement la mandoline
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
CH686365A5 (de) 1992-10-06 1996-03-15 Werner Hofliger Mobilkran.
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
AU732306B2 (en) 1997-10-14 2001-04-12 Chugai Seiyaku Kabushiki Kaisha Potentiator for antibody against lymphoid tumor
US5843597A (en) 1997-12-01 1998-12-01 Eveready Battery Company, Inc. Ribbed gasket for miniature galvanic cell
JPH11279009A (ja) 1998-03-26 1999-10-12 Sumitomo Chem Co Ltd 除草剤組成物
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
DE69939939D1 (de) * 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
DK1240326T3 (da) 1999-11-15 2009-06-02 Innate Pharma Udlösende receptor der er involveret i naturlig cytotoxicitet medieret af humane naturlige dræberceller og antistoffer som identificerer denne receptor
PE20010833A1 (es) 1999-12-20 2001-09-08 Siemens Energy And Automation Inc Sistema, procedimiento y aparato para conectar fuentes electricas en serie bajo plena carga
FR2804027B1 (fr) 2000-01-20 2002-08-30 Monoclonal Antibodies Therapeu Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
CZ20023203A3 (cs) 2000-03-24 2003-08-13 Micromet Ag Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D
WO2002034290A2 (en) * 2000-10-23 2002-05-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
EP1343822B1 (en) 2000-12-18 2012-05-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Means for the diagnosis and therapy of ctcl
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
US7858300B2 (en) * 2001-10-19 2010-12-28 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
JP2006514024A (ja) * 2002-12-23 2006-04-27 イネイト・ファーマ Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
PL1639013T3 (pl) 2003-07-02 2013-02-28 Innate Pharma Przeciwciała pan-kir2dl receptorów NK i ich zastosowanie w diagnostyce i leczeniu
EP1648507B1 (en) 2003-07-24 2017-01-25 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
US8210374B2 (en) 2003-12-02 2012-07-03 Alfred Knox Harpole Rackable collapsible stackable unit

Also Published As

Publication number Publication date
CA2532547A1 (en) 2005-02-03
IL172679A (en) 2011-04-28
AU2004258747B2 (en) 2009-11-19
CN102772798A (zh) 2012-11-14
NO20150493L (no) 2006-01-24
PL1648507T3 (pl) 2017-07-31
NO341586B1 (no) 2017-12-11
CN1829530A (zh) 2006-09-06
JP5665702B2 (ja) 2015-02-04
EP1648507B1 (en) 2017-01-25
JP5642328B2 (ja) 2014-12-17
US20110008335A1 (en) 2011-01-13
LT1648507T (lt) 2017-04-25
BRPI0412890A (pt) 2006-10-03
CN104645327A (zh) 2015-05-27
PT1648507T (pt) 2017-03-20
JP2012051889A (ja) 2012-03-15
US7803376B2 (en) 2010-09-28
DK1648507T3 (en) 2017-05-01
NO337619B1 (no) 2016-05-09
ZA200601584B (en) 2007-05-30
JP6290751B2 (ja) 2018-03-07
WO2005009465A1 (en) 2005-02-03
CA2532547C (en) 2020-02-25
KR101299599B1 (ko) 2013-08-23
HRP20170342T1 (hr) 2017-05-19
BRPI0412890B1 (pt) 2019-05-14
EP2292264A3 (en) 2012-12-19
KR20060038461A (ko) 2006-05-03
US10059765B2 (en) 2018-08-28
EP1648507A1 (en) 2006-04-26
EP2292264A2 (en) 2011-03-09
US20050037002A1 (en) 2005-02-17
RU2396981C2 (ru) 2010-08-20
US20150299319A1 (en) 2015-10-22
NO20056049L (no) 2006-04-24
US9090876B2 (en) 2015-07-28
ES2619171T3 (es) 2017-06-23
BRPI0412890B8 (pt) 2021-05-25
AU2004258747A1 (en) 2005-02-03
CY1118978T1 (el) 2018-01-10
JP2014240426A (ja) 2014-12-25
IL172679A0 (en) 2006-04-10
HUE033129T2 (en) 2017-11-28
KR20120063562A (ko) 2012-06-15
JP2006528626A (ja) 2006-12-21
CN102772798B (zh) 2016-01-13
RU2006105642A (ru) 2006-06-27

Similar Documents

Publication Publication Date Title
IL172679A0 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
IL176749A0 (en) ANTIBODIES TO MAdCAM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL175935A0 (en) Solid forms of anti-egfr antibodies
EP1567157A4 (en) METHODS OF USE AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE SYNDROMES
IL175306A0 (en) Compositions and dosage forms for enhanced absorption
HUP0500851A3 (en) Process for the preparation of rosuvastatin
EP1664343A4 (en) METHODS AND COMPOSITIONS FOR GENERATING HUMAN ANTIBODY GENES OF GERMINAL LINE
HK1090639A1 (en) Immunosuppressant compounds and compositions
HK1087929A1 (zh) 免疫抑制劑化合物和組合物
EG23458A (en) Set of elements for assemlying structures
IL178786A0 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
SI1587542T1 (sl) Uporaba anti-cd100 protiteles
AU2003256805A8 (en) Compounds compositions and methods
ZA200600025B (en) Methods and compositions for interferon therapy
EP1773883A4 (en) PRODUCTION OF ANTICANCER ANTIBODIES USING MASKED CANCER CELLS AS IMMUNOGENS
AU2003201826A8 (en) Compounds for delivering substances into cells
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
EP1578775A4 (en) NEW COMPOSITIONS AND METHOD FOR GENERATING MHC CLASS II COMPOUNDS BY PEPTIDE EXCHANGE
GB0324147D0 (en) Functionilisation of particles
GB2392618B (en) Compositions for therapeutic use
AU2003302822A8 (en) Antibodies to treat cancer
AU2003298022A8 (en) Particles for imaging cells
HK1104800A1 (en) Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
GB0315494D0 (en) Compounds which bind to the active site of protein kinase enzymes
PL1687006T3 (pl) Kompozycje farmaceutyczne do leczenia zaburzeń czynności nerek